Aridis Pharmaceuticals Statistics
Total Valuation
Aridis Pharmaceuticals has a market cap or net worth of 53. The enterprise value is 4.81 million.
| Market Cap | 53 |
| Enterprise Value | 4.81M |
Important Dates
The next estimated earnings date is Friday, November 1, 2024.
| Earnings Date | Nov 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Aridis Pharmaceuticals has 53.32 million shares outstanding. The number of shares has increased by 88.34% in one year.
| Shares Outstanding | 53.32M |
| Shares Change (YoY) | +88.34% |
| Shares Change (QoQ) | +2.26% |
| Owned by Insiders (%) | 4.36% |
| Owned by Institutions (%) | 10.53% |
| Float | 44.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.21 |
| EV / Sales | 0.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.27 |
Financial Position
The company has a current ratio of 0.24
| Current Ratio | 0.24 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -4.40% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 604,297 |
| Profits Per Employee | -30,865 |
| Employee Count | 37 |
| Asset Turnover | 2.40 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -100.00% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -100.00% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 25.68 |
| Average Volume (20 Days) | 51,816 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Aridis Pharmaceuticals had revenue of 22.36 million and -1.14 million in losses. Loss per share was -0.04.
| Revenue | 22.36M |
| Gross Profit | 5.21M |
| Operating Income | -656,000 |
| Pretax Income | -1.14M |
| Net Income | -1.14M |
| EBITDA | -347,000 |
| EBIT | -656,000 |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 35,000 in cash and 4.84 million in debt, giving a net cash position of -4.81 million or -0.09 per share.
| Cash & Cash Equivalents | 35,000 |
| Total Debt | 4.84M |
| Net Cash | -4.81M |
| Net Cash Per Share | -0.09 |
| Equity (Book Value) | -11.80M |
| Book Value Per Share | -0.26 |
| Working Capital | -13.37M |
Cash Flow
In the last 12 months, operating cash flow was -17.89 million and capital expenditures -49,000, giving a free cash flow of -17.93 million.
| Operating Cash Flow | -17.89M |
| Capital Expenditures | -49,000 |
| Free Cash Flow | -17.93M |
| FCF Per Share | -0.34 |
Margins
Gross margin is 23.28%, with operating and profit margins of -2.93% and -5.11%.
| Gross Margin | 23.28% |
| Operating Margin | -2.93% |
| Pretax Margin | -5.11% |
| Profit Margin | -5.11% |
| EBITDA Margin | -1.55% |
| EBIT Margin | -2.93% |
| FCF Margin | -80.21% |
Dividends & Yields
Aridis Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -88.34% |
| Shareholder Yield | -88.34% |
| Earnings Yield | -3,991,400.00% |
| FCF Yield | -33,634,095.99% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aridis Pharmaceuticals has an Altman Z-Score of -39.72. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -39.72 |
| Piotroski F-Score | n/a |